Lipid-lowering effect of tenofovir in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 682-683

  Fabbiani, Massimiliano ^a   Bracciale, Laura ^a   Doino, Maria ^a   Sidella, Letizia ^a   Farina, Salvatore ^a   di Cristo, Valentina ^a   Cauda, Roberto ^a   de Luca, Andrea ^a,b   di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antiretroviral therapy; Cardiovascular risk; Cholesterol; Simplification

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LETTER; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTICHOLESTEREMIC AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 79951530133     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq464     Document Type: Letter

References (6)

1. Tungsiripat M, Kitch D, Glesby MJ et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24: 1781-4.
2. Atazanavir/ritonavir and Lamivudine for treatment Simplification, AtLaS study. http://clinicaltrials.gov/ct2/show/NCT00885482 (10 October 2010, date last accessed).
3. Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events. December 2004. http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf (10 October 2010, date last accessed).
4. Arribas JR, Horban A, Gerstoft J et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010; 24: 223-30.
5. Randell PA, Jackson AG, Zhong L et al. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther 2010; 15: 227-33.
6. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.